Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and argenx SE

SG&A Expenses: Takeda vs. argenx SE

__timestampTakeda Pharmaceutical Company Limitedargenx SE
Wednesday, January 1, 20146126130000004241601.57
Thursday, January 1, 20156507730000005392385.38
Friday, January 1, 20166190610000007370036.73
Sunday, January 1, 201762810600000014970357
Monday, January 1, 201871759900000031413266
Tuesday, January 1, 201996473700000072279461
Wednesday, January 1, 2020875663000000183907682
Friday, January 1, 2021886361000000307644000
Saturday, January 1, 2022997309000000472132000
Sunday, January 1, 20231053819000000709539000
Monday, January 1, 20241053819000000
Loading chart...

Infusing magic into the data realm

A Comparative Analysis of SG&A Expenses in the Pharmaceutical Sector

In the ever-evolving pharmaceutical industry, operational costs play a pivotal role in shaping a company's financial health. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Takeda Pharmaceutical Company Limited and argenx SE, from 2014 to 2023.

Takeda, a Japanese giant, has consistently demonstrated a robust financial strategy, with SG&A expenses peaking at approximately 1.05 trillion yen in 2023, marking a 72% increase from 2014. In contrast, argenx SE, a Belgian biotech firm, has shown a remarkable growth trajectory, with expenses surging by over 16,600% during the same period, albeit from a much smaller base.

This stark contrast highlights the diverse financial strategies and growth phases of these companies, offering valuable insights into their operational efficiencies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025